Can stem‑cell therapy effectively treat restless legs syndrome, or is any benefit likely a placebo effect?

Stem Cell Therapy for Restless Legs Syndrome: Not Evidence-Based

Your suspicion is correct—stem cell therapy has no established role in treating restless legs syndrome, and any perceived benefit is almost certainly a placebo effect. The most recent and comprehensive 2025 American Academy of Sleep Medicine (AASM) clinical practice guidelines make no mention whatsoever of stem cell therapy as a treatment option for RLS 1.

What the Evidence Actually Shows

The 2025 AASM guidelines comprehensively reviewed all available treatments for RLS and established clear recommendations based on rigorous evidence 1. Stem cells are completely absent from this guideline, which evaluated everything from established medications to alternative therapies like valerian and acupuncture. If stem cell therapy had any legitimate evidence base, it would have been reviewed and included.

Evidence-Based First-Line Treatments

According to the most current guidelines, the strong recommendations (highest level) for RLS treatment are 1:

• Gabapentin enacarbil (strong recommendation, moderate certainty)
• Gabapentin (strong recommendation, moderate certainty)
• Pregabalin (strong recommendation, moderate certainty)
• IV ferric carboxymaltose for patients with ferritin ≤100 ng/mL or transferrin saturation <20% (strong recommendation, moderate certainty)

These gabapentinoids achieve approximately 70% improvement rates in clinical trials versus 40% with placebo 2.

Why Placebo Effects Are Particularly Strong in RLS

RLS is uniquely susceptible to placebo responses for several reasons:

1. Subjective symptom reporting: RLS diagnosis and severity assessment rely entirely on patient-reported sensations with no objective biomarkers
2. Symptom variability: RLS naturally waxes and wanes, making it difficult to distinguish treatment effects from natural fluctuation
3. High baseline placebo response: Studies show approximately 40% placebo response rates in RLS trials 2
4. Expectation effects: Expensive, novel-sounding treatments like "stem cells" create powerful expectation bias

What to Tell Your Patient

Redirect them to evidence-based care:

1. Check iron status first: Measure serum ferritin and transferrin saturation. Supplement with ferrous sulfate (325-650 mg daily or every other day) if ferritin ≤100 ng/mL 1, 2

2. Review medications: Discontinue any serotonergic antidepressants, dopamine antagonists, or antihistamines like diphenhydramine that worsen RLS 1, 2

3. Start gabapentinoid therapy: If symptoms persist after addressing iron and medications, initiate gabapentin, gabapentin enacarbil, or pregabalin 1

4. Avoid dopamine agonists as first-line: While pramipexole and ropinirole work short-term, they carry 7-10% annual risk of augmentation (iatrogenic worsening) 1, 2

The Stem Cell Problem

There are zero published randomized controlled trials of stem cell therapy for RLS. The comprehensive systematic reviews of both pharmacological 3, 2 and non-pharmacological interventions 4, 5 for RLS—which included everything from acupuncture to yoga to transcranial magnetic stimulation—found no evidence for stem cell therapy.

Common Pitfalls to Avoid

• Don't dismiss the patient's experience: Acknowledge they feel better, but explain this doesn't validate the treatment mechanism
• Don't let them continue ineffective expensive therapy: Stem cell treatments are costly and divert resources from proven interventions
• Don't ignore the underlying condition: Use this as an opportunity to optimize their evidence-based RLS management

The Bottom Line

Your patient is experiencing a placebo response to an unproven, expensive intervention. The 2025 AASM guidelines 1 represent the most authoritative, current evidence on RLS treatment and make no mention of stem cells. Steer them toward gabapentinoids and iron supplementation, which have strong evidence for actual therapeutic benefit beyond placebo.